Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $36.0352W HIGH $67.70
Volume
1.04 M
Value Traded
68.32 M
Short % Float
3.07%
Days to Cover
4.3
+1.88%Week
+16.55%1 Month
+14.35%3 Month
+30.21%6 Month
+34.7%5 Year
+23.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
37.98 B
EPS (TTM)
1.83
P/E Ratio
36.08
Ent. Value
45.99 B
Total Shares
575.00 M
Float Shares
418.41 M
Insiders
6.32%
Institutions
86.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
RPRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Royalty Pharma plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Royalty Pharma plc
58Total events
3Upcoming
17Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Grant / FundingCorporate
Royalty Pharma donates $7.5 million to Blood Cancer United's Therapy Acceleration Program
blood cancersource ↗
▲Partnership / LicenserusfertideCorporate
Zealand Pharma enters into royalty purchase and sale agreement with Royalty Pharma for rusfertide economics
polycythemia verasource ↗
▲Partnership / LicensecliramitugCorporate
Neurimmune sells portion of royalty interest in cliramitug to Royalty Pharma for up to $425M
amyloid transthyretin cardiomyopathy (ATTR-CM)source ↗
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
▲Partnership / LicenseJNJ-4804Corporate
R&D co-funding arrangement with Johnson & Johnson for JNJ-4804
autoimmune diseasessource ↗
▲Partnership / LicenseZiiheraCorporate
Acquired royalty interest in Ziihera from Zymeworks for $250 million
HER2-positive metastatic biliary tract cancersource ↗
◆Management ChangeCorporate
Henry Fernandez steps down from Royalty Pharma Board of Directors
▲Quarterly UpdateCorporate
Royalty Pharma reports Q2 2025 results with Portfolio Receipts growth of 20% to $727 million
▲Partnership / LicenseCorporate
Royalty Pharma announced groundbreaking funding agreement with Revolution Medicines
◆Management ChangeCorporate
Appointment of Carole Ho and Elizabeth Weatherman to Board of Directors
▼Equity OfferingCorporate
Royalty Pharma repurchased $1 billion of Class A ordinary shares in first half of 2025
▲AcquisitionCorporate
Royalty Pharma completed acquisition of external manager RP Management, LLC
▲Milestone PaymentAdstiladrinCorporate
Royalty Pharma received $200 million milestone payment related to Adstiladrin
bladder cancersource ↗
▲Partnership / LicenselitifilimabCorporate
R&D funding arrangement with Biogen for litifilimab
lupussource ↗
◆Oral PresentationPresentation
Royalty Pharma presentation at 43rd Annual J.P. Morgan Healthcare Conference
▲Milestone PaymentCorporate
Royalty Pharma received $27M pro rata milestone payment from AstraZeneca for Airsupra
▲Equity OfferingCorporate
Royalty Pharma authorized new $3B share repurchase program; intends to repurchase $2B in 2025
◆AcquisitionCorporate
Royalty Pharma agreed to acquire external manager RP Management for ~$1.1B
▲Partnership / LicenseCorporate
Royalty Pharma sold MorphoSys Development Funding Bonds for $511M upfront cash
●Milestone PaymentCobenfyCorporate
Royalty Pharma to make $25M milestone payment to PureTech Health in Q4 2024
▲Quarterly UpdateCorporate
Royalty Pharma reported Q2 2024 results and raised full year 2024 guidance
▲Partnership / LicensefrexalimabCorporate
Royalty Pharma acquires royalties on Sanofi's frexalimab from ImmuNext for ~$525M
●Milestone PaymentolpasiranCorporate
Royalty Pharma makes $50M milestone payment to Arrowhead related to olpasiran
◆Oral PresentationPresentation
Royalty Pharma presentation at 42nd Annual J.P. Morgan Healthcare Conference
▲Milestone PaymentZavzpretCorporate
Royalty Pharma receives $475 million accelerated milestone payment from Pfizer following Zavzpret FDA approval
acute treatment of migrainesource ↗
▲Quarterly UpdateCorporate
Royalty Pharma raises full year 2023 Adjusted Cash Receipts guidance to $2,850-$2,950 million
▲Partnership / LicenseCorporate
Royalty Pharma agrees to acquire royalty interest in TRELEGY ELLIPTA from Theravance and Innoviva for $1.31B upfront plus up to $300M milestones
▲Partnership / LicenseampreloxetineCorporate
Royalty Pharma provides $25M upfront and potential $15M regulatory milestone for ampreloxetine development in exchange for low- to mid-single digit royalty
symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophysource ↗
▲Grant / FundingCorporate
Royalty Pharma launched five-year, $7.5 million alliance with Blood Cancer United focused on healthcare disparities in blood cancer
blood cancersource ↗
▲Partnership / LicenseCorporate
Royalty Pharma launched five-year, $7.5 million alliance with Blood Cancer United
blood cancersource ↗
▲Partnership / LicenseCorporate
Royalty Pharma and MorphoSys announce $2.025 billion strategic funding partnership
Past FDA Catalysts and PDUFA Decisions
How RPRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-19 | Aficamten | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Royalty Pharma plc is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RPRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pelacarsen | atherosclerotic cardiovascular disease and elevated lipoprotein(a) | Phase 3 | 2026-09-04 | did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placeboRead More | Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Urist MarshallOfficer (EVP, Research & Investments) | Sell | -4,126 | $57.10 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RPRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.5 % | 2.71 M | 87.00 K |
Ownership Trends
RPRX Short Interest
Shares sold short, counted twice a month.
3.07%
Short % of Float
of tradable shares sold short
12.8M
Shares Sold Short
-0.3% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RPRX ranks across every disease it competes in
Competitive Position is a premium feature
See how RPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRPRX News
RPRX▼ -0.4%today
Royalty Pharma reports third quarter 2026 results
Royalty Pharma reported strong third quarter results for 2026, with Royalty Receipts increasing by 9% to $883 million. The company raised its full year guidance for Portfolio Receipts to between $3,500 million and $3,550 million. Positive developments included FDA approvals for several therapies and strong growth in its royalty portfolio.
Read more →RPRXRoyalty Pharma declares fourth quarter 2026 dividend
Royalty Pharma plc has announced a dividend of $0.235 per Class A ordinary share for the fourth quarter of 2026. This dividend will be paid on December 10, 2026, to shareholders recorded by November 13, 2026. The company is recognized as a major player in the biopharmaceutical sector, funding innovation and acquiring royalties from various therapies.
Read more →RPRXRoyalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Royalty Pharma plc has announced that it will release its third quarter 2026 financial results on November 4, 2026, prior to the opening of U.S. financial markets. The company will also hold a conference call and webcast at 8:00 a.m. ET on the same day. Interested parties can access the call via the company's website.
Read more →RPRXBlood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
Blood Cancer United announced a $7.5 million donation from Royalty Pharma to expand its Therapy Acceleration Program. This funding supports venture capital investments in early-stage biotech companies developing blood cancer therapies. The program has previously helped six therapies gain FDA approval or inclusion in clinical guidelines. Royalty Pharma serves as the first and largest corporate donor under this updated initiative.
Read more →RPRXRoyalty Pharma to present at upcoming investor conferences
Royalty Pharma plc will participate in two upcoming investor conferences in September 2026. The Morgan Stanley 24th Annual Global Healthcare Conference is scheduled for September 14, and the BofA Global Research Global Healthcare Conference will take place on September 23. The company emphasizes its role in funding innovation in the biopharmaceutical sector.
Read more →RPRX▼ -5.3%on this news
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing cardiovascular events. Despite this setback, Royalty Pharma anticipates recovering its investment through a structured funding agreement with Ionis. The company reaffirms its financial targets for 2030, indicating confidence in its broader portfolio.
Read more →RPRXRoyalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Royalty Pharma has entered a $100 million funding agreement with Zealand Pharma for rusfertide, a potential first-in-class therapy for polycythemia vera. This collaboration aims to support Zealand Pharma's innovative pipeline and enhance its financial resources for future growth. The FDA has set a PDUFA goal date for rusfertide's NDA in Q3 2026.
Read more →RPRXZealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Zealand Pharma has entered a $100 million royalty purchase agreement with Royalty Pharma for its economic interests in rusfertide, a potential therapy for polycythemia vera. The deal includes an upfront payment of $50 million, with the remaining amount due in a year. Zealand Pharma aims to use the funds to support its strategic priorities under its Metabolic Frontier 2030 strategy.
Read more →RPRXRoyalty Pharma reports second quarter 2026 results
Royalty Pharma reported strong second quarter results for 2026, with Royalty Receipts growth of 14% to $768 million and Portfolio Receipts growth of 6% to $773 million. The company raised its full year guidance for Portfolio Receipts to between $3.4 billion and $3.5 billion. Recent acquisitions and a robust transaction pipeline contribute to its optimistic outlook.
Read more →RPRXRoyalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
Royalty Pharma has appointed Greg Raskin as Senior Vice President, Head of Academic Initiatives, effective August 2026. Raskin will lead outreach efforts with academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. His extensive background in medicine and investing is expected to strengthen partnerships with the scientific community.
Read more →RPRXRoyalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
Royalty Pharma has acquired a royalty interest in AstraZeneca's cliramitug for up to $425 million, including an upfront payment of $125 million. Cliramitug is a Phase 3 antibody targeting TTR amyloidosis with cardiomyopathy, aiming to address unmet medical needs in this progressive disease. The transaction is expected to enhance Royalty Pharma's development-stage pipeline and capitalize on the growing ATTR-CM market.
Read more →RPRXNeurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma
Neurimmune has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including an upfront payment of $125 million. This deal will provide Neurimmune with non-dilutive funding to support its R&D pipeline. Cliramitug, an investigational monoclonal antibody, aims to address amyloid transthyretin cardiomyopathy (ATTR-CM) and is currently in a Phase 3 trial under AstraZeneca's management.
Read more →RPRXRoyalty Pharma declares third quarter 2026 dividend
Royalty Pharma plc has announced a dividend of $0.235 per Class A ordinary share for the third quarter of 2026. This dividend will be distributed on September 10, 2026, to shareholders on record by August 14, 2026. The company is recognized as a major player in biopharmaceutical royalties and funding innovation.
Read more →RPRXRoyalty Pharma to announce second quarter 2026 financial results on August 5, 2026
Royalty Pharma plc has announced it will report its second quarter 2026 financial results on August 5, 2026, before the U.S. markets open. A conference call and webcast will take place at 8:00 a.m. Eastern Time on the same day. The company is recognized for its significant role in funding biopharmaceutical innovation.
Read more →RPRXRoyalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 9, 2026. The event will feature a fireside chat at 4:00 p.m. ET, and the webcast will be available on the company's website. Royalty Pharma is recognized for its significant role in funding biopharmaceutical innovation.
Read more →RPRXRoyalty Pharma reports first quarter 2026 results
Royalty Pharma plc reported strong financial results for Q1 2026, with Portfolio Receipts increasing by 10% to $925 million and Royalty Receipts growing by 13%. The company raised its full-year guidance for Portfolio Receipts, anticipating between $3,325 million and $3,450 million. Key developments include successful R&D collaborations and positive clinical outcomes for products in its portfolio.
Read more →RPRXHENRY FERNANDEZ STEPS DOWN FROM ROYALTY PHARMA S BOARD OF DIRECTORS
Henry Fernandez has stepped down as Lead Independent Director of Royalty Pharma, effective August 13, 2025. He joined the Board in July 2020 and has played a crucial role in the company's growth since its IPO. The CEO praised his contributions, stating that Fernandez's leadership helped achieve significant milestones. The company plans to appoint a new Lead Independent Director soon.
Read more →RPRXROYALTY PHARMA REPORTS SECOND QUARTER 2025 RESULTS
Royalty Pharma plc reported strong financial results for Q2 2025, achieving a 20% increase in Portfolio Receipts, reaching $727 million. The firm raised its full-year guidance and completed a strategic acquisition of its external manager, marking its transition to an integrated company. A notable funding agreement with Revolution Medicines further supports its growth strategy. However, operating cash flow dropped significantly, and a legal dispute over royalties with Vertex raises concerns about future revenue stability.
Read more →RPRXROYALTY PHARMA APPOINTS CAROLE HO AND ELIZABETH WEATHERMAN TO THE COMPANY S BOARD OF DIRECTORS
Royalty Pharma announced the appointments of Carole Ho and Elizabeth Weatherman to its Board of Directors. Ho brings extensive experience in therapeutic development at Denali Therapeutics, while Weatherman has a solid background in healthcare investing with Warburg Pincus. These additions are expected to bolster the board's capabilities and support Royalty Pharma's long-term strategy. The company aims to strengthen its position as a leader in biopharmaceutical royalties.
Read more →About Royalty Pharma plc
Headquarters110 EAST 59TH STREET, NEW YORK, NY, 10022
BIOPHARMAWATCH ELITE PLUS
Trade the next RPRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime